MMP‐3 (–1171 5A/6A; Lys45Glu) variants affect serum levels of matrix metalloproteinase (MMP)‐3 and correlate with severity of COPD: A study of MMP‐3, MMP‐7 and MMP‐12 in a Tunisian population

Bchir, Sarra; Nasr, Hela Ben; Garrouch, A.; Anes, Amel ben; Abbassi, Ammar; Tabka, Zouhaïr; Chahed, Karim

doi:10.1002/jgm.2999

Cited by 13 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several studies that have tried to identify SNPs associated with lung function decline with controversial results. Genetic variants in NLRP, MMP3, IL8, TIMP1, and EDN1 have been previously associated with the worsening of COPD and FEV1 decline in different populations [35][36][37][38][39]. In addition, Gian-Andri et al [40] described that in the SAPALDIA cohort those subjects who carry on at least one Z allele had a higher risk for accelerate lung function decline, especially in population subgroups characterized by low-grade inflammation.…”

Section: Discussionmentioning

confidence: 99%

Haplotype in SERPINA1 (AAT) Is Associated with Reduced Risk for COPD in a Mexican Mestizo Population

Ponce-Gallegos

Pérez-Rubio

García-Carmona

et al. 2019

IJMS

View full text Add to dashboard Cite

Protease inhibitor S (PiS) and protease inhibitor Z (PiZ) variants in the SERPINA1 gene are the main genetics factors associated with COPD; however, investigations about other polymorphisms are scanty. The aim of this study was to evaluate two missense single nucleotide polymorphisms (SNPs) (rs709932 and rs1303) in the SERPINA1 gene in Mexican mestizo patients with chronic obstructive pulmonary disease (COPD) related to tobacco smoking and biomass-burning exposure. 1700 subjects were genotyped and divided into four groups: COPD related to tobacco smoking (COPD-S, n = 297), COPD related to biomass-burning exposure (COPD-BB, n = 178), smokers without COPD (SWOC, n = 674), and biomass-burning exposed subjects (BBES, n = 551) by real-time PCR. Moreover, the patients’ groups were divided according to their exacerbations’ frequency. We carried out a haplotype analysis. We did not find differences in allele and genotype frequencies between groups in unadjusted and adjusted analyses, neither with these SNPs and lung function decline. Exacerbations’ frequency is not associated with these SNPs. However, we found a haplotype with major alleles (CT) associated with reduced risk for COPD (p < 0.05). Our analysis reveals that SNPs different from PiS and PiZ (rs709932 and rs1303) in the SERPINA1 gene are not associated with COPD and lung function decline in a Mexican mestizo population. However, a haplotype shaped by both major alleles (CT haplotype) is associated with reduced risk for COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Haplotype in SERPINA1 (AAT) Is Associated with Reduced Risk for COPD in a Mexican Mestizo Population

Ponce-Gallegos

Pérez-Rubio

García-Carmona

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…[4] Since their discovery,M MPs have emerged as an intriguing target in pharmaceuticalr esearch. [5][6][7][8][9] Due to the involvement of members of the MMP family in am ultitude of severe diseases, such as cancer, [10][11][12][13][14][15][16] arthritis, [17,18] chronic obstructive pulmonary disease (COPD), [19][20][21] or sepsis, [22][23][24][25] great efforts weret aken to modulate MMP activity to possibly treat diseases in which MMP activity is out of balance. [26,27] Due to side effects evolving from al ack of selectivity and insufficient knowledge aboutt he relevance of the target family in pathological processes, no compound designed as an MMP inhibitor has reached the market so far,a nd clinicalt rials have failed.…”

Section: Introductionmentioning

confidence: 99%

Design and Structural Evolution of Matrix Metalloproteinase Inhibitors

Fischer

Senn

Riedl

2019

Chemistry A European J

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) are involved in a multitude of severe diseases. Despite MMPs being considered druggable targets, past drug‐discovery programs have not delivered the anticipated clinical benefits. This review examines the latest structural evolution of small‐molecule inhibitors of MMPs, with a focus on the development of novel chemical entities with improved affinity and selectivity profiles. X‐ray crystallographic data of the protein targets and cocrystal structures with inhibitors proved to be key for the success achieved during this ambitious endeavor. An evolutionary view on the structural diversity generated for this class of molecules is provided. This encouraging development paves the way for the clinical utilization of this class of highly relevant therapeutic targets. The structure‐based design of superior MMP inhibitors highlights the power of this technique and displays strategies for the development of treatment options based on the modulation of challenging drug targets.

show abstract

“…[ 13 ] Although the results from a meta-analysis conducted in 2014 suggest that genetic polymorphisms in MMP12 gene may be strongly implicated in the development of COPD, [ 25 ] some studies since then have not supported this view. [ 23 – 24 ] the association between MMP12 polymorphism and COPD remains unclear. It is necessary to update previous systematic review about the genetic polymorphism of MMP-12 gene and the risk of COPD MMP-12, which can provide a further reference for the diagnosis and potential therapeutic targets of COPD.…”

Section: Discussionmentioning

confidence: 99%

“…[ 20 , 21 ] However, other studies have found that MMP-12 polymorphism are not associated with COPD risk. [ 13 , 22 – 24 ] Therefore, the association between MMP12 polymorphism and COPD remains unclear. Although a similar systematic review based on COPD was published in 2014, [ 25 ] new studies have occurred since.…”

Section: Introductionmentioning

confidence: 99%

Association of matrix metalloproteinase-12 polymorphisms with chronic obstructive pulmonary disease risk

Yang¹,

Zhang²,

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD) is a multifactorial disease with gene-environment interaction leading to airflow limitation through the respiratory tract. Reports on the association of matrix metalloproteinase 12 (MMP-12) polymorphisms with COPD have been controversial. A new systematic evaluation which could examine whether MMP-12 mutations are associated with the susceptibility to COPD is needed. Methods: We will search PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure and Google Scholar to obtain eligible case-control studies for meta-analysis. The time is limited from the construction of the library to July 2020. Two investigators systematically will extract relevant data within those included studies. The odds ratio and 95% confidence intervals will be used to assess the genetic association between the allelic, dominant and recessive models of MMP-12 gene polymorphisms and COPD risk. Stata 12.0 software and Revman 5.3 will be adopted for statistical analysis. This protocol reported under the Preferred Reporting ltems for Systematic Reviews and Meta-Analyses Protocols statement. Results: This study will provide a better understanding of the association between MMP-12 polymorphisms and COPD risk. Conclusion: Publishing this protocol will minimise the possibility of bias due to post hoc changes to the analysis protocol.

show abstract

MMP‐3 (–1171 5A/6A; Lys45Glu) variants affect serum levels of matrix metalloproteinase (MMP)‐3 and correlate with severity of COPD: A study of MMP‐3, MMP‐7 and MMP‐12 in a Tunisian population

Abstract: Background: The present study aimed to examine the role of matrix metalloproteinase

Cited by 13 publications

References 48 publications

Haplotype in SERPINA1 (AAT) Is Associated with Reduced Risk for COPD in a Mexican Mestizo Population

Haplotype in SERPINA1 (AAT) Is Associated with Reduced Risk for COPD in a Mexican Mestizo Population

Design and Structural Evolution of Matrix Metalloproteinase Inhibitors

Association of matrix metalloproteinase-12 polymorphisms with chronic obstructive pulmonary disease risk

Contact Info

Product

Resources

About